Tepotinib Clinical Trials
6 recruitingDrug
Phase 24Phase 11Phase 31
Showing 1–6 of 6 trials
Recruiting
Phase 2
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center47 enrolled1 locationNCT06106802
Recruiting
Phase 2
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network56 enrolled267 locationsNCT06031688
Recruiting
Phase 3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique133 enrolled29 locationsNCT06908993
Recruiting
Phase 1
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Advanced Cancer
Institute of Cancer Research, United Kingdom19 enrolled4 locationsNCT05782361
Recruiting
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Advanced CancerSolid TumorHaematological Malignancy
Helsinki University Central Hospital250 enrolled5 locationsNCT05159245
Recruiting
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
CancerNeoplasmNeoplasia+1 more
The Netherlands Cancer Institute1,550 enrolled36 locationsNCT02925234